He said at the time: “One of the benefits of Brexit will be faster access to life-saving treatments on the NHS.”
The other nations involved are Canada, Australia, Switzerland, Singapore, and Brazil.
The lung cancer drug – called Osimertinib – is made by AstraZeneca and sold under the brand name Tagrisso.
Mr Hancock said: “It is absolutely vital NHS patients have access to the most promising, cutting-edge treatments as quickly as possible.
“Leaving the EU presented us with the opportunity to join Project Orbis – a collaboration with the top regulators around the world – to speed up the time it takes to get new medicines to patients.
“I am delighted we are able to see the first results – a groundbreaking drug for lung cancer which will soon benefit hundreds of patients and I look forward to seeing what further innovations it will bring to the table.”
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) will make the final decision to authorise any medicines.
Chief executive Dr June Raine said: “We know that the earlier we can treat patients, the better their outcomes.
“The MHRA is cementing the UK’s global position at the centre of life sciences and healthcare access.”
This post originally appeared on Daily Express :: Health Feed